Study of Theories About Myopia Progression (STAMP)

October 27, 2022 updated by: Ohio State University
At this time, we do not know what causes a child to become more nearsighted (myopic). STAMP will help us better understand nearsightedness in children. Children will be randomly chosen to wear regular glasses (single vision lenses) or no-line bifocal glasses (progressive addition lenses) for the first year of the study. All children will wear regular glasses for the second year of the study. STAMP will compare how the eye changes shape in the two groups to help us understand why children become nearsighted. The two theories of myopia progression that are being evaluated are based on different factors. One theory is based on environmental factors such as extended near work while the other theory is based on genetically coded factors.

Study Overview

Detailed Description

Eligible children will be enrolled, randomized, and followed at six-month intervals for two years with all children wearing single vision lenses for the second year. At each visit, complete measurements of the components of the eye will be made to explain the mechanism responsible for the Progressive Addition Lens (PAL) treatment effect and why it occurs mainly during the first year of bifocal wear (Gwiazda et al. 2003). While hyperopic retinal blur (blur at the back of the eye) due to accommodative lag (poor focusing when doing close work) has been proposed as a possible mechanism driving myopia progression (Gwiazda et al. 1993), others have shown that accommodative lag accompanies rather than precedes the onset of myopia (Mutti et al., 2006). This suggests that accommodative lag is a result of another possible mechanism resulting in myopia progression such as crystalline lens-induced ciliary-choroidal tension (a model in which the lens in the eye is stretched and is not as good at focusing up close) (Mutti et al., 2000). According to this proposed mechanism, high accommodative lag in myopia results from increased crystalline lens tension that is transmitted through the choroid (an outside layer of the eye). This tension results in restricted equatorial (the vertical dimension of the eye) eye growth with no axial (front to back) restriction to eye growth and yields a prolate ocular shape (an eye that is longer than it is wide) in myopes (Mutti et al., 2000).

Comparisons: Refractive error (glasses prescription), axial length (length of the eye), peripheral eye shape, accommodation (focusing ability), corneal shape (shape of the front of the eye), anterior chamber depth, crystalline lens thickness and curvatures (shape of the lens in the eye), central and peripheral higher-order aberrations (how well light focuses in the eye), and phoria (eye alignment) will be measured at six-month intervals. The primary study outcome is refractive error measured by cycloplegic autorefraction. Comparison of the biometric data collected both during the first year when the PAL intervention is present and during the second year when the PAL intervention is removed will allow us to differentiate between the two theories under consideration. We will also evaluate whether the modest PAL treatment effect that has been reported during the first year of PAL wear is permanent.

Study Type

Interventional

Enrollment (Actual)

85

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Columbus, Ohio, United States, 43210
        • The Ohio State University College of Optometry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 11 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 6 to 11 years of age
  • Best corrected vision of at least 20/30 in each eye
  • Birth weight > 1250g

(The criteria below will be evaluated at a screening visit to find out if the child can participate)

  • Accommodative lag >= 1.30 D (for a 4D stimulus)
  • At least -0.75 D myopia in each meridian measured with cycloplegic autorefraction but not more than -4.50 D in each meridian in each eye
  • Esophoria at near if more than -2.25 D spherical equivalent (high myopia)
  • Astigmatism < 2.00 DC in each eye
  • Anisometropia < 2.00 D

Exclusion Criteria:

  • Strabismus (eye turn)
  • History of contact lens wear
  • History of previous bifocal wear
  • Diabetes mellitus

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PAL
Progressive Addition Spectacle Lenses (PALs) with a +2.00 D add worn for first year off study. Single Vision Lenses worn for second year of study.
Progressive addition lenses (PAL) with a +2.00 D add.
Other Names:
  • PAL
Active Comparator: SVL
Single Vision Lenses (SVLs) worn both years of the study.
Single vision spectacle lenses.
Other Names:
  • SVL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Cycloplegic autorefraction
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Phoria
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months
Accommodative lag
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months
AC/A ratio
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months
Corneal shape and thickness
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months
Intraocular pressure
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months
Peripheral ocular shape
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months
Central and peripheral aberrations
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months
Crystalline lens thickness and curvature
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months
Anterior chamber depth
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months
Axial length
Time Frame: Baseline, 6, 12, 18, and 24 months
Baseline, 6, 12, 18, and 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David A Berntsen, OD, PhD, University of Houston
  • Principal Investigator: Karla Zadnik, OD, PhD, Ohio State University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2006

Primary Completion (Actual)

July 1, 2010

Study Completion (Actual)

July 1, 2010

Study Registration Dates

First Submitted

June 7, 2006

First Submitted That Met QC Criteria

June 7, 2006

First Posted (Estimate)

June 8, 2006

Study Record Updates

Last Update Posted (Actual)

October 28, 2022

Last Update Submitted That Met QC Criteria

October 27, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2005H0157
  • K12EY015447 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe